Despite Zoetis' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish ...

Zoetis Inc. (NYSE:ZTS) is one of the best defensive stocks to invest in according to analysts. On July 10, Bank of America ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

Zoetis (NYSE:ZTS) added ~7% in the premarket on Tuesday after the animal health company exceeded Street forecasts with its Q2 ...

Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% ...

Zoetis Inc. Q2 2025 earnings highlight 8% organic revenue growth, raised guidance, and strong performance from Simparica and Key Dermatology franchises.

Zoetis beats Q2 estimates with strong pet product sales and raises full-year guidance despite livestock sales decline and Librela weakness.

Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET. Company Participants. Kristin C. Peck - CEO & Director Steven Frank - Vice President of Investor ...

The company raised its full-year 2025 guidance, now expecting revenue between $9.45 billion and $9.6 billion, representing ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and vaccines for pets, sending the animal healthcare company's shares surging ...

We came across a bullish thesis on Zoetis Inc. on Bob’s Payment Stock Substack by Bob Hammel. In this article, we will ...

The global Veterinary Diagnostics Market, valued at US$3.42 billion in 2024 stood at US$3.68 billion in 2025 and is projected ...